Medigen Vaccine Biologics Corporation (TPEX:6547)
Taiwan · Delayed Price · Currency is TWD 52.70
+0.90 (1.74%)
Oct 16, 2026, 1:30 PM CST
Medigen Vaccine Biologics Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 17,325 | 12,410 | 11,851 | 23,035 | 22,785 | 63,653 | |
Market Cap Growth | 42.82% | 4.72% | -48.55% | 1.10% | -64.20% | 192.75% |
Enterprise Value | 16,388 | 11,035 | 10,382 | 21,271 | 20,540 | 62,660 |
Last Close Price | 52.70 | 37.75 | 36.05 | 70.10 | 69.50 | 200.91 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 45.14 |
Forward PE | 57.28 | 218.70 | 39.19 | - | - | - |
PS Ratio | 30.19 | 20.24 | 19.57 | 59.12 | 62.42 | 19.40 |
PB Ratio | 4.87 | 3.57 | 3.08 | 5.99 | 4.53 | 13.61 |
P/TBV Ratio | 4.90 | 3.59 | 3.10 | 6.05 | 4.57 | 13.77 |
P/FCF Ratio | - | - | 1835.64 | - | - | 142.64 |
P/OCF Ratio | - | - | 290.80 | - | - | 109.77 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 28.56 | 18.00 | 17.14 | 54.59 | 56.27 | 19.10 |
EV/EBITDA Ratio | - | - | - | - | - | 58.45 |
EV/EBIT Ratio | - | - | - | - | - | 65.02 |
EV/FCF Ratio | - | - | 1608.05 | - | - | 140.41 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.31 | 0.08 | 0.09 | 0.51 | 0.39 | 0.04 |
Debt / EBITDA Ratio | - | - | - | - | - | 0.17 |
Debt / FCF Ratio | - | - | 52.50 | - | - | 0.42 |
Net Debt / Equity Ratio | -0.26 | -0.43 | -0.41 | -0.46 | -0.45 | -0.44 |
Net Debt / EBITDA Ratio | 16.20 | 10.32 | 60.26 | 1.62 | 1.60 | -1.91 |
Net Debt / FCF Ratio | 4.31 | 14.93 | -244.21 | 3.42 | 1.69 | -4.59 |
Asset Turnover | 0.13 | 0.15 | 0.12 | 0.06 | 0.06 | 0.75 |
Inventory Turnover | 0.41 | 0.59 | 0.50 | 0.25 | 0.76 | 2.84 |
Quick Ratio | 17.43 | 10.35 | 9.54 | 1.99 | 12.48 | 6.54 |
Current Ratio | 22.37 | 12.77 | 11.94 | 2.21 | 15.38 | 8.48 |
Return on Equity (ROE) | -4.62% | -7.69% | -2.09% | -26.14% | -30.39% | 36.08% |
Return on Assets (ROA) | -2.54% | -4.00% | -1.74% | -11.29% | -15.18% | 13.71% |
Return on Capital Employed (ROCE) | -3.90% | -7.10% | -3.50% | -29.60% | -22.00% | 19.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.96% | -2.27% | -0.68% | -5.04% | -6.47% | 2.22% |
FCF Yield | -1.26% | -0.80% | 0.05% | -2.26% | -5.94% | 0.70% |
Buyback Yield / Dilution | -0.01% | -0.03% | -0.10% | -1.50% | -0.73% | -15.82% |